Cannabinoid receptor signalling in neurodegenerative diseases: A potential role for membrane fluidity disturbance

M. MacCarrone, G. Bernardi, A. Finazzi Agrò, D. Centonze

Research output: Contribution to journalArticle

Abstract

Type-1 cannabinoid receptor (CB 1) is the most abundant G-protein-coupled receptor (GPCR) in the brain. CB 1 and its endogenous agonists, the so-called 'endocannabinoids (eCBs)', belong to an ancient neurosignalling system that plays important functions in neurodegenerative and neuroinflammatory disorders like Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. For this reason, research on the therapeutic potential of drugs modulating the endogenous tone of eCBs is very intense. Several GPCRs reside within subdomains of the plasma membranes that contain high concentrations of cholesterol: the lipid rafts. Here, the hypothesis that changes in membrane fluidity alter function of the endocannabinoid system, as well as progression of particular neurodegenerative diseases, is described. To this end, the impact of membrane cholesterol on membrane properties and hence on neurodegenerative diseases, as well as on CB 1 signalling in vitro and on CB 1-dependent neurotransmission within the striatum, is discussed. Overall, present evidence points to the membrane environment as a critical regulator of signal transduction triggered by CB 1, and calls for further studies aimed at better clarifying the contribution of membrane lipids to eCBs signalling. The results of these investigations might be exploited also for the development of novel therapeutics able to combat disorders associated with abnormal activity of CB 1.

Original languageEnglish
Pages (from-to)1379-1390
Number of pages12
JournalBritish Journal of Pharmacology
Volume163
Issue number7
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Cannabinoid Receptors
Endocannabinoids
Membrane Fluidity
Neurodegenerative Diseases
Membranes
Combat Disorders
Cholesterol
Therapeutic Human Experimentation
Amyotrophic Lateral Sclerosis
Membrane Lipids
G-Protein-Coupled Receptors
Synaptic Transmission
Multiple Sclerosis
Parkinson Disease
Signal Transduction
Alzheimer Disease
Cell Membrane
Lipids
Brain
Pharmaceutical Preparations

Keywords

  • cholesterol
  • CRAC domain
  • endocannabinoid
  • membrane lipids
  • neurodegeneration
  • neurotransmission
  • palmitoylation
  • striatum

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cannabinoid receptor signalling in neurodegenerative diseases : A potential role for membrane fluidity disturbance. / MacCarrone, M.; Bernardi, G.; Agrò, A. Finazzi; Centonze, D.

In: British Journal of Pharmacology, Vol. 163, No. 7, 08.2011, p. 1379-1390.

Research output: Contribution to journalArticle

@article{b9e2f836dbaa458a8f47b7e7412257d5,
title = "Cannabinoid receptor signalling in neurodegenerative diseases: A potential role for membrane fluidity disturbance",
abstract = "Type-1 cannabinoid receptor (CB 1) is the most abundant G-protein-coupled receptor (GPCR) in the brain. CB 1 and its endogenous agonists, the so-called 'endocannabinoids (eCBs)', belong to an ancient neurosignalling system that plays important functions in neurodegenerative and neuroinflammatory disorders like Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. For this reason, research on the therapeutic potential of drugs modulating the endogenous tone of eCBs is very intense. Several GPCRs reside within subdomains of the plasma membranes that contain high concentrations of cholesterol: the lipid rafts. Here, the hypothesis that changes in membrane fluidity alter function of the endocannabinoid system, as well as progression of particular neurodegenerative diseases, is described. To this end, the impact of membrane cholesterol on membrane properties and hence on neurodegenerative diseases, as well as on CB 1 signalling in vitro and on CB 1-dependent neurotransmission within the striatum, is discussed. Overall, present evidence points to the membrane environment as a critical regulator of signal transduction triggered by CB 1, and calls for further studies aimed at better clarifying the contribution of membrane lipids to eCBs signalling. The results of these investigations might be exploited also for the development of novel therapeutics able to combat disorders associated with abnormal activity of CB 1.",
keywords = "cholesterol, CRAC domain, endocannabinoid, membrane lipids, neurodegeneration, neurotransmission, palmitoylation, striatum",
author = "M. MacCarrone and G. Bernardi and Agr{\`o}, {A. Finazzi} and D. Centonze",
year = "2011",
month = "8",
doi = "10.1111/j.1476-5381.2011.01277.x",
language = "English",
volume = "163",
pages = "1379--1390",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Cannabinoid receptor signalling in neurodegenerative diseases

T2 - A potential role for membrane fluidity disturbance

AU - MacCarrone, M.

AU - Bernardi, G.

AU - Agrò, A. Finazzi

AU - Centonze, D.

PY - 2011/8

Y1 - 2011/8

N2 - Type-1 cannabinoid receptor (CB 1) is the most abundant G-protein-coupled receptor (GPCR) in the brain. CB 1 and its endogenous agonists, the so-called 'endocannabinoids (eCBs)', belong to an ancient neurosignalling system that plays important functions in neurodegenerative and neuroinflammatory disorders like Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. For this reason, research on the therapeutic potential of drugs modulating the endogenous tone of eCBs is very intense. Several GPCRs reside within subdomains of the plasma membranes that contain high concentrations of cholesterol: the lipid rafts. Here, the hypothesis that changes in membrane fluidity alter function of the endocannabinoid system, as well as progression of particular neurodegenerative diseases, is described. To this end, the impact of membrane cholesterol on membrane properties and hence on neurodegenerative diseases, as well as on CB 1 signalling in vitro and on CB 1-dependent neurotransmission within the striatum, is discussed. Overall, present evidence points to the membrane environment as a critical regulator of signal transduction triggered by CB 1, and calls for further studies aimed at better clarifying the contribution of membrane lipids to eCBs signalling. The results of these investigations might be exploited also for the development of novel therapeutics able to combat disorders associated with abnormal activity of CB 1.

AB - Type-1 cannabinoid receptor (CB 1) is the most abundant G-protein-coupled receptor (GPCR) in the brain. CB 1 and its endogenous agonists, the so-called 'endocannabinoids (eCBs)', belong to an ancient neurosignalling system that plays important functions in neurodegenerative and neuroinflammatory disorders like Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis. For this reason, research on the therapeutic potential of drugs modulating the endogenous tone of eCBs is very intense. Several GPCRs reside within subdomains of the plasma membranes that contain high concentrations of cholesterol: the lipid rafts. Here, the hypothesis that changes in membrane fluidity alter function of the endocannabinoid system, as well as progression of particular neurodegenerative diseases, is described. To this end, the impact of membrane cholesterol on membrane properties and hence on neurodegenerative diseases, as well as on CB 1 signalling in vitro and on CB 1-dependent neurotransmission within the striatum, is discussed. Overall, present evidence points to the membrane environment as a critical regulator of signal transduction triggered by CB 1, and calls for further studies aimed at better clarifying the contribution of membrane lipids to eCBs signalling. The results of these investigations might be exploited also for the development of novel therapeutics able to combat disorders associated with abnormal activity of CB 1.

KW - cholesterol

KW - CRAC domain

KW - endocannabinoid

KW - membrane lipids

KW - neurodegeneration

KW - neurotransmission

KW - palmitoylation

KW - striatum

UR - http://www.scopus.com/inward/record.url?scp=79960290509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960290509&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01277.x

DO - 10.1111/j.1476-5381.2011.01277.x

M3 - Article

C2 - 21323908

AN - SCOPUS:79960290509

VL - 163

SP - 1379

EP - 1390

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 7

ER -